

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 September 2023 (28.09.2023)



(10) International Publication Number
WO 2023/183594 A2

(51) International Patent Classification:
C12N 15/86 (2006.01) A61K 48/00 (2006.01)

(21) International Application Number:
PCT/US2023/016270

(22) International Filing Date:
24 March 2023 (24.03.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/323,830 25 March 2022 (25.03.2022) US
63/326,236 31 March 2022 (31.03.2022) US
63/341,841 13 May 2022 (13.05.2022) US
63/393,196 28 July 2022 (28.07.2022) US
63/438,164 10 January 2023 (10.01.2023) US

(71) Applicant: **ASKLEPIOS BIOPHARMACEUTICAL, INC.** [US/US]; 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US).

(72) Inventors: **BANKIEWICZ, Krystof S.**; 5815 Balmoral Drive, Oakland, California 94619 (US). **KELLS, Adrian P.**; 525 Nelson Rising Lane, Apartment 404, San Francisco, California 94158 (US). **VAN LAAR, Amber**; c/o Asklepios BioPharmaceutical, Inc., 20 T.W. Alexander Drive, Suite 110, Research Triangle Park, North Carolina 27709 (US). **FIANDACA, Massimo S.**; 3912 Brookdale Blvd, Castro Valley, California 94546 (US).

(74) Agent: **JODOIN, Jeanne Nicole** et al.; Nixon Peabody LLP, 53 State Street, Exchange Place, Boston, Massachusetts 02109 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON'S DISEASE




FIG. 26

(57) Abstract: Aspects of the disclosure relate to compositions and methods useful for treating Parkinson's disease. In some embodiments, the disclosure provides a method for treating Parkinson's disease comprising administration of a viral vector comprising a GDNF nucleic acid sequence. In some embodiments, administration is locally to the subject putamen. In some embodiments, administration is systemically, e.g., via the viral vector comprising a modified viral capsid, such as for preferentially targeting cells in the CNS or PNS.

[Continued on next page]

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*